Delving into the Latest Updates on RetinaPharma Technologies, Inc. with Synapse

概览

关联

1

项与 RetinaPharma Technologies, Inc. 相关的药物

RT-001(RetinaPharma)

靶点

TPI1

作用机制

TPI1抑制剂

在研机构-

原研机构

RetinaPharma Technologies, Inc.

在研适应症-

非在研适应症

青光眼 [+1]

最高研发阶段无进展

首次获批国家/地区-

首次获批日期-

100 项与 RetinaPharma Technologies, Inc. 相关的临床结果

登录后查看更多信息

0 项与 RetinaPharma Technologies, Inc. 相关的专利（医药）

登录后查看更多信息

1

项与 RetinaPharma Technologies, Inc. 相关的文献（医药）

Drug Delivery Technology

Thermally labile liposomes for treatment of blinding retinal disease

作者: O'Donnell, Francis E. ; Fuller, Terry A. ; Santos, Carlos

A review on the use of PhotoTarget angiog. (PTA) and PhotoTarget occlusion (PTO) technol. in the treatment of age-related macular degeneration.PTA and PTO rely on a well-defined heating mechanism to release the content of the thermally-labile liposomes and ensure a robust and simple way of targeting specific tissue within the treated organ.They allow greater refinement of treatment areas and therefore markedly reduce the damage to surrounding tissue in relation to traditional procedures.The approach is particularly effective at increasing the range of photosensitizers available, and thus allows greater control over individual treatments.

100 项与 RetinaPharma Technologies, Inc. 相关的药物交易

登录后查看更多信息

100 项与 RetinaPharma Technologies, Inc. 相关的转化医学

登录后查看更多信息